Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
3.720
-0.050 (-1.33%)
At close: Nov 20, 2026, 4:00 PM EST
3.710
-0.010 (-0.27%)
After-hours: Nov 20, 2026, 7:56 PM EST
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $5.49M in the twelve months ending September 30, 2026, down -13.07% year-over-year. In the year 2025, Taysha Gene Therapies had annual revenue of $9.77M with 17.28% growth. That makes Taysha Gene Therapies the 39,713th largest company in the world by revenue and 5,260th in the United States.
Revenue (ttm)
$5.49M
Revenue Growth
-13.07%
P/S Ratio
221.13
Revenue / Employee
$55,404
Employees
99
Market Cap
1.21B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.77M | 1.44M | 17.28% |
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Innoviva | 438.32M |
| MannKind | 413.37M |
| Novavax | 411.65M |
| Ocular Therapeutix | 50.38M |
| Silence Therapeutics | 456.00K |
TSHA News
- 10 days ago - Taysha Gene Therapies Earnings Call Transcript: Q3 2026 - Transcripts
- 10 days ago - Taysha Gene Therapies Quarterly report: Q3 2026 - Filings
- 10 days ago - Taysha Gene Therapies Earnings release: Q3 2026 - Filings
- 10 days ago - Taysha Gene Therapies reports Q3 EPS (10c), consensus (12c) - TheFly
- 10 days ago - Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 16 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 - GlobeNewsWire
- 7 weeks ago - Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting - GlobeNewsWire